retatrutide clinical trials phase ESC 2024: improves lipid and cardiovascular risk profile in II trial VisualAbstract: Retatrutide reduces body weight

Notably, GLP-1 receptor activation in afferent arterioles induces vasodilation, thereby enhancing glomerular filtration while simultaneously reducing intraglomerular pressure

Source: Phase 3 TRIUMPH-4 trial (68 weeks, 445 participants) Nausea is the most common side effect overall and usually the worst during the first few weeks and during dose increases

However, its important to note that both Semaglutide GLP-1 and Liraglutide can cause gastrointestinal side effects, with a slightly higher incidence in patients taking Semaglutide GLP-1

This bioactive lipid induces a powerful GPR119 mediated-GLP-1 secretion in vitro and ex-vivo from intestines of wild type, but not GPR119 deficient mice